To compare FDG-PET/unenhanced MRI and FDG-PET/diagnostic CT in detecting infiltration in patients with newly diagnosed Hodgkin lymphoma (HL). The endpoint was equivalence between PET/MRI and PET/CT in correctly defining the revised Ann Arbor staging system. Seventy consecutive patients with classical-HL were prospectively investigated for nodal and extra-nodal involvement during pretreatment staging with same-day PET/CT and PET/MRI. Findings indicative of malignancy with the imaging procedures were regarded as lymphoma infiltration; in case of discrepancy, positive-biopsy and/or response to treatment were evidenced as lymphoma. Sixty of the 70 (86%) patients were evaluable having completed the staging program. Disease staging based on either PET/MRI or PET/CT was correct for 54 of the 60 patients (90% vs. 90%), with difference between proportions of 0.0 (95% CI, −9 to 9%; P=0.034 for the equivalence test). As compared with reference standard, invasion of lymph nodes was identified with PET/MRI in 100% and with PET/CT in 100%, of the spleen with PET/MRI in 66% and PET/CT in 55%, of the lung with PET/MRI in 60% and PET/CT in 100%, of the liver with PET/MRI in 67% and PET/CT in 100%, and of the bone with PET/MRI in 100% and PET/CT in 50%. The only statistically significant difference between PET/MRI and PET/CT was observed in bony infiltration detection rates. For PET/CT, iodinate contrast medium infusions’ average was 86 mL, and exposure to ionizing radiation was estimated to be 4-fold higher than PET/MRI. PET/MRI is a promising safe new alternative in the care of patients with HL.

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial / Picardi, M.; Cavaliere, C.; Della Pepa, R.; Nicolai, E.; Soricelli, A.; Giordano, C.; Pugliese, N.; Rascato, M. G.; Cappuccio, I.; Campagna, G.; Cerchione, C.; Vigliar, E.; Troncone, G.; Mascolo, M.; Franzese, M.; Castaldo, R.; Salvatore, M.; Pane, F.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 100:6(2021), pp. 1525-1535. [10.1007/s00277-021-04537-5]

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial

Della Pepa R.;Nicolai E.;Soricelli A.;Pugliese N.;Rascato M. G.;Cappuccio I.;Campagna G.;Cerchione C.;Vigliar E.;Mascolo M.;
2021

Abstract

To compare FDG-PET/unenhanced MRI and FDG-PET/diagnostic CT in detecting infiltration in patients with newly diagnosed Hodgkin lymphoma (HL). The endpoint was equivalence between PET/MRI and PET/CT in correctly defining the revised Ann Arbor staging system. Seventy consecutive patients with classical-HL were prospectively investigated for nodal and extra-nodal involvement during pretreatment staging with same-day PET/CT and PET/MRI. Findings indicative of malignancy with the imaging procedures were regarded as lymphoma infiltration; in case of discrepancy, positive-biopsy and/or response to treatment were evidenced as lymphoma. Sixty of the 70 (86%) patients were evaluable having completed the staging program. Disease staging based on either PET/MRI or PET/CT was correct for 54 of the 60 patients (90% vs. 90%), with difference between proportions of 0.0 (95% CI, −9 to 9%; P=0.034 for the equivalence test). As compared with reference standard, invasion of lymph nodes was identified with PET/MRI in 100% and with PET/CT in 100%, of the spleen with PET/MRI in 66% and PET/CT in 55%, of the lung with PET/MRI in 60% and PET/CT in 100%, of the liver with PET/MRI in 67% and PET/CT in 100%, and of the bone with PET/MRI in 100% and PET/CT in 50%. The only statistically significant difference between PET/MRI and PET/CT was observed in bony infiltration detection rates. For PET/CT, iodinate contrast medium infusions’ average was 86 mL, and exposure to ionizing radiation was estimated to be 4-fold higher than PET/MRI. PET/MRI is a promising safe new alternative in the care of patients with HL.
2021
PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial / Picardi, M.; Cavaliere, C.; Della Pepa, R.; Nicolai, E.; Soricelli, A.; Giordano, C.; Pugliese, N.; Rascato, M. G.; Cappuccio, I.; Campagna, G.; Cerchione, C.; Vigliar, E.; Troncone, G.; Mascolo, M.; Franzese, M.; Castaldo, R.; Salvatore, M.; Pane, F.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 100:6(2021), pp. 1525-1535. [10.1007/s00277-021-04537-5]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/886225
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact